We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Disseminated Histoplasmosis, Pulmonary Tuberculosis, and Cytomegalovirus Disease in a Renal Transplant Recipient after Infection with SARS-CoV-2.
- Authors
Mauricio, Carvallo-Venegas; Angélica, Fuentes-López Elsa; de Jesús, Andrade-Ortega Antonio; Rodrigo, Torres-Baranda José; Aldo, Carrasco-Carrizosa; Ignacio, Cerrillos-Gutierrez José; Jorge, Andrade-Sierra
- Abstract
Introduction. Infection with SARS-CoV-2 increases the risk of acute graft dysfunction (AGD) in renal transplant recipients (RTR), and the risk of concurrently presenting with opportunistic infections is also increased. There is no current consensus on the management of immunosuppression during SARS-CoV-2 infection in RTR. Case Presentation. A 35-year-old male RTR from a living related donor presented with SARS-CoV-2 infection (January 2021). Two months later, despite alterations to his immunosuppression regimen (tacrolimus (TAC) was reduced by 50%, and the mycophenolic acid (MMF) was suspended with the remission of symptoms), the patient presented with pulmonary tuberculosis, pneumonia due to respiratory syncytial virus (RSV), cytomegalovirus (CMV) pneumonitis, and histoplasmosis (HP). Management was initiated with antituberculosis medications, ganciclovir, antibiotics, and liposomal amphotericin B, and the immunosuppressants were suspended, yet the patient's evolution was catastrophic and the outcome fatal. Conclusion. We recommend that in RTR post-COVID-19, the immunosuppression regimen should be gradually reinstated along with strict vigilance in observing for highly prevalent coinfections (TB, HP, and CMV).
- Subjects
HISTOPLASMOSIS; CYTOMEGALOVIRUS diseases; TUBERCULOSIS; KIDNEY transplantation; SARS-CoV-2; RESPIRATORY syncytial virus
- Publication
Case Reports in Transplantation, 2022, p1
- ISSN
2090-6943
- Publication type
Case Study
- DOI
10.1155/2022/8042168